STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Clinical trials for STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy hopes to tackle rare skin cancer
Disease control TerminatedThis phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advan…
Matched conditions: STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat skin cancers in early trial
Disease control OngoingThis early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in 38 adults with advanced mycosis fungoides or Sezary syndrome (types of skin lymphoma). The goal is to find the safest dose and see if the drugs can shrink tumors. Duvelisib blocks certain enzymes…
Matched conditions: STAGE IIB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC